A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus

bayram, fahri; Atıcı, Yasemin; baskol, gulden

doi:10.1515/tjb-2022-0013

A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus

Yasemin ATICI, (Lokman Hekim Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya, Ankara, Türkiye)

Gülden BAŞKOL, (Lokman Hekim Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Bölümü, Ankara, Türkiye)

Fahri BAYRAM (Erciyes Üniversitesi, Tıp Fakültesi, Kayseri, Türkiye)

Türk Biyokimya Dergisi

2 1

Yıl: 2022 Cilt: 47 Sayı: 6 Sayfa Aralığı: 775 - 782 Metin Dili: İngilizce DOI: 10.1515/tjb-2022-0013 İndeks Tarihi: 22-05-2023

A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus

Öz:

Objectives: Metformin is the first choice for type 2 diabetes mellitus (T2DM) treatment in the guidelines and is used in combination with many drugs. Growth arrest-specific protein 6 (Gas6)/Axl signaling plays a role in many metabolic disorders. This study aims to investigate the effects of metformin and metformin-insulin combination used in patients with T2DM on Gas6, Axl, and soluble Axl (sAxl) levels. Methods: A total of 71 patients diagnosed with T2DM and 21 healthy subjects were divided into 4 groups control, diet and exercises recommended (DER), metformin, and metformin + insulin. Diabetic patients were treated with metformin only or with a metformin-insulin combination and monitored for six months. Gas6, Axl, and sAxl levels of subjects’ sera obtained from their baseline and posttherapeutic sixth month blood samples were measured by ELISA methods. Results: Compared to baseline, the sixth month Gas6 and Axl levels of metformin and metformin + insulin groups significantly decreased (p<0.05). However, there was no statistically significant difference in sAxl values for these two groups of patients. Conclusions: The use of metformin in diabetic patients may be beneficial for inhibiting the Gas6/Axl pathway. This study presents a new aspect of the pleiotropic effects of metformin. This study will be clinically useful for designing therapeutic approaches targeting Gas6/Axl.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Diabetes atlas [Online], 9th ed. 2021. Available from: https://www.diabetesatlas.org/upload/resources/material/ 20200302_133351_IDFATLAS9e-final-web.pdf [Accessed 16 Apr 2022].
2. Standards of medical care in diabetes centered on evolving evidence, technology, and individualized care [Online]; 2021. Available from: https://www.diabetes.org/newsroom/pressreleases/ 2020/ADA-releases-2021-standards-of-medical-carein- diabetes [Accessed 10 Aug 2021].
3. European Association for the Study of Diabetes. 56th EASD annual meeting of the European association for the study of diabetes. Diabetologia 2020;63:1–485.
4. The society of endocrinology and metabolism of Turkey (SEMT). Clinical practice guideline for diagnosis, treatment, and followup of diabetes mellitus and its complications - 2019. The Society of Endocrinology and Metabolism of Turkey (SEMT); 2019, Turkey.
5. Piskovatska V, Stefanyshyn N, Storey KB, Vaiserman AM, Lushchak O. Metformin as a geroprotector: experimental and clinical evidence. Biogerontology 2019;20:33–48.
6. Zhou J, Massey S, Story D, Li L. Metformin: an old drug with new applications. Int J Mol Sci 2018;19:2863.
7. Kelestimur F, Ünlühizarci K, Bayram F, Sahin Y, Tutus A. Metformin and polycystic ovary syndrome. Clin Endocrinol 2000; 52:244–6.
8. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res 2019;11:3295.
9. Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin 2018;50:133–43.
10. Tsou W-I, Nguyen K-QN, Calarese DA, Garforth SJ, Antes AL, Smirnov SV, et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem 2014;289: 25750–63.
11. Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer 2017;116:415–23.
12. Kariolis MS, Miao YR, Jones DS, Kapur S, Mathews II, Giaccia AJ, et al. An engineered Axl’decoy receptor effectively silences the Gas6-Axl signaling axis. Nat Chem Biol 2014;10: 977–83.
13. Budagian V, Bulanova E, Orinska Z, Duitman E, Brandt K, Ludwig A, et al. Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum. Mol Cell Biol 2005;25:9324–39.
14. Ekman C, Stenhoff J, Dahlback B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 2010;8:838–44.
15. Lee CH, Changchien CY, Hung YJ. Targeting inflammation in type 2 diabetes by antibody-mediated Tyro-3, Axl, Mer receptor activation. Wiley Online Library 2015;6:491–4.
16. Van der Meer JH, van der Poll T, van ‘t Veer C. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood. Am J Hematol 2014;123:2460–9.
17. Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253–70.
18. Lega IC, Lipscombe LL. Diabetes, obesity, and cancer— pathophysiology and clinical implications. Endocr Rev 2020;41: 33–52.
19. Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, type 2 diabetes, and cancer risk. Front Oncol 2021;10:615375.
20. Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. J Clin Oncol 2016;34:4261–9.
21. Madsen KS, Kähler P, Kähler LKA, Madsbad S, Gnesin F, Metzendorf MI, et al. Metformin and second or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2019;4: CD012368.
22. Chawla R, Madhu S, Makkar B, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab 2020;24:1–122.
23. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med 2015;66:17–29.
24. Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract 2018;143:409–19.
25. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
26. Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms, and clinical applications. Mol Cancer 2019;18:1–22.
27. Dihingia A, Kalita J, Manna P. Implication of a novel Glacontaining protein, Gas6 in the pathogenesis of insulin resistance, impaired glucose homeostasis, and inflammation: a review. Diabetes Res Clin Pract 2017;128:74–82.
28. Hung YJ, Lee CH, Chu NF, Shieh YS. Plasma protein growth arrest– specific 6 levels are associated with altered glucose tolerance, inflammation, and endothelial dysfunction. Diabetes Care 2010; 33:1840–4.
29. Kuo FC, Hung YJ, Shieh YS, Hsieh CH, Hsiao FC, Lee CH. The levels of plasma growth arrest-specific protein 6 is associated with insulin sensitivity and inflammation in women. Diabetes Res Clin Pract 2014;103:304–9.
30. Lee C-H, Chu N-F, Shieh Y-S, Hung Y-J. The growth arrest-specific 6 (Gas6) gene polymorphism c.834+7G>A is associated with type 2 diabetes. Diabetes Res Clin Pract 2012;95:201–6.
31. Cavet ME, Smolock EM, Ozturk OH, World C, Pang J, Konishi A, et al. Gas6–Axl receptor signaling is regulated by glucose in vascular smooth muscle cells. Arterioscler Thromb Vasc 2008;28: 886–91.
32. Axelrod H, Pienta KJ. Axl as a mediator of cellular growth and survival. Oncotarget 2014;5:8818–52.
33. Tai K, Shieh Y, Lee C, Shiah S, Wu C-W. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1. Oncogene 2008;27:4044–55.
34. Ikhlas S, Ahmad M. Metformin: insights into its anticancer potential with special reference to AMPK dependent and independent pathways. Life Sci 2017; 185:53–62.
35. Kim N-Y, Lee H-Y, Lee C. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. Int J Oncol 2015;47: 353–60.
36. Saito T, Itoh M, Tohda S. Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase. Leukemia Res 2020;94: 106383.

APA	Atıcı Y, baskol g, bayram f (2022). A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. , 775 - 782. 10.1515/tjb-2022-0013
Chicago	Atıcı Yasemin,baskol gulden,bayram fahri A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. (2022): 775 - 782. 10.1515/tjb-2022-0013
MLA	Atıcı Yasemin,baskol gulden,bayram fahri A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. , 2022, ss.775 - 782. 10.1515/tjb-2022-0013
AMA	Atıcı Y,baskol g,bayram f A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. . 2022; 775 - 782. 10.1515/tjb-2022-0013
Vancouver	Atıcı Y,baskol g,bayram f A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. . 2022; 775 - 782. 10.1515/tjb-2022-0013
IEEE	Atıcı Y,baskol g,bayram f "A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus." , ss.775 - 782, 2022. 10.1515/tjb-2022-0013
ISNAD	Atıcı, Yasemin vd. "A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus". (2022), 775-782. https://doi.org/10.1515/tjb-2022-0013

APA	Atıcı Y, baskol g, bayram f (2022). A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. Türk Biyokimya Dergisi, 47(6), 775 - 782. 10.1515/tjb-2022-0013
Chicago	Atıcı Yasemin,baskol gulden,bayram fahri A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. Türk Biyokimya Dergisi 47, no.6 (2022): 775 - 782. 10.1515/tjb-2022-0013
MLA	Atıcı Yasemin,baskol gulden,bayram fahri A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. Türk Biyokimya Dergisi, vol.47, no.6, 2022, ss.775 - 782. 10.1515/tjb-2022-0013
AMA	Atıcı Y,baskol g,bayram f A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. Türk Biyokimya Dergisi. 2022; 47(6): 775 - 782. 10.1515/tjb-2022-0013
Vancouver	Atıcı Y,baskol g,bayram f A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus. Türk Biyokimya Dergisi. 2022; 47(6): 775 - 782. 10.1515/tjb-2022-0013
IEEE	Atıcı Y,baskol g,bayram f "A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus." Türk Biyokimya Dergisi, 47, ss.775 - 782, 2022. 10.1515/tjb-2022-0013
ISNAD	Atıcı, Yasemin vd. "A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus". Türk Biyokimya Dergisi 47/6 (2022), 775-782. https://doi.org/10.1515/tjb-2022-0013